A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
about
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.Temozolomide in paediatric high-grade glioma: a key for combination therapy?Temozolomide: a milestone in neuro-oncology and beyond?Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade gliomaDose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.The efficacy of temozolomide for recurrent glioblastoma multiforme.Economics of Malignant Gliomas: A Critical Review.Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiformeThe future of high-grade glioma: Where we are and where are we going.Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.Canadian recommendations for the treatment of glioblastoma multiforme.Dose-dense temozolomide: is it still promising?Recent developments on immunotherapy for brain cancer.Impact of temozolomide on immune response during malignant glioma chemotherapyCytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future.Standards of care for treatment of recurrent glioblastoma--are we there yet?Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).Health-related quality of life in patients with high-grade gliomaNew (alternative) temozolomide regimens for the treatment of glioma.Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience.Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.Temozolomide dosing regimens for glioma patients.The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation.Management and treatment recommendations for World Health Organization Grade III and IV gliomas.Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroidsIndications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience.Extended continuous oral temozolomide in patients with progressive metastatic renal cell carcinoma not responding to interferon alpha 2b.Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma.Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.Current therapeutic approaches to diffuse grade II and III gliomas.
P2860
Q33358912-1F47E0E6-F14D-4A6F-8AF8-0FBCF831B9D8Q33361765-4EBD919A-5C2D-40D6-B428-EAA8C1368282Q33372340-ABD8AA45-964B-4BF6-B4AF-4EA8830BB7E0Q33384898-4BD6322A-A830-489F-88E5-923CC09D4CF0Q33391731-9A7CDDC2-9F51-44AD-A7D4-ABD9858B04DAQ33973844-948911BD-97B0-4F3F-A7B1-767C55DEE6DCQ34062033-12CAD3C1-3429-4AC1-9F4D-244B87F4EF70Q34186787-C191BB1C-A840-4AB7-9BBF-8A5815B1BC38Q34297519-6A56BD8E-3AB6-4958-B9B7-11F27A7B0973Q34968951-97DD0647-FA8A-4401-A044-2A2F8F92BE15Q35008709-61A4B46E-6168-4DF7-98BF-A9D1887F124BQ35027024-5CEAE568-4F79-4D50-BAF3-F0932DD43455Q35114090-83903105-2081-4E88-B78D-D7692C4F067DQ35676452-58B7D607-2939-45C4-8993-9C84BD0FEEA4Q35855352-55ADA0D2-ACA5-4901-8820-C85108D32918Q35943654-CE4E9FD6-E5F2-4485-A2BD-11B8CAFCC380Q35992355-13F5F9AD-C29E-40B5-A2CE-99BE372D39D2Q36362798-4A337B2C-1F3B-48BB-92AC-C5F9766AFD7FQ36429731-0206FBDE-60AB-4AF5-BED4-EED684C70388Q36500401-7EDBCC0F-7CA3-4FC0-A92E-A13F3DE3EB3CQ36544101-BA1C9A04-F4D7-49AD-A3AB-5CD235C357F7Q36611825-803DC1DF-FC52-4F92-979F-16A064614170Q37217109-2ED5271A-AFF1-49A5-955F-E782F1FCF3ADQ37261125-A2C58748-A446-4DCD-B492-131C24623A93Q37366417-E45D34A4-4547-46F3-9B5D-39531E1C4F3AQ37900207-97A8B176-0C5A-4581-8B14-2CD9D3C1A7F0Q37995906-EF18C9B5-E75F-4808-A149-273069AE606AQ38205133-6AE8B97C-C1DC-40B4-8CDF-DB2EFEBBE940Q38720644-6AC18805-1B07-40C9-89C6-FA99983B0DF3Q39228006-2BD56EA4-9074-47DC-8D0F-140E150ED659Q41706326-F29367D3-2748-4DF4-8E6E-500EA5218E89Q42560730-CF7BA228-7C33-4B8E-A017-C01ECE8DD51EQ46231452-07A9004E-6B56-45C4-B743-72BC9EAA39AAQ46908702-D7E0585A-45C2-4E15-92AA-C29CB8E0633DQ47436703-70E0B65E-4131-4E15-BB5D-6998A4FF8AE6Q48280437-ABDDCCB7-71ED-4616-85D4-E32552B7EC51Q49317056-7981A4F8-207C-44B0-8B04-999160536386
P2860
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
@ast
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
@en
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
@nl
type
label
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
@ast
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
@en
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
@nl
prefLabel
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
@ast
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
@en
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
@nl
P2093
P356
P1433
P1476
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
@en
P2093
Jeffrey J Raizer
Kimberley A Bazylewicz
Lauren E Abrey
Mark G Malkin
Raja B Khan
P356
10.1215/15228517-4-1-39
P407
P577
2002-01-01T00:00:00Z